Drug Profile
Compound X - Teijin Pharma
Alternative Names: CDK inhibitor - Teijin Pharma; CDK4/6 inhibitor - Teijin Pharma; Cyclin dependent kinase 4/6 inhibitor - Teijin Pharma; Cyclin dependent kinase inhibitor - Teijin PharmaLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Antirheumatics
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Japan (PO)
- 28 Dec 2017 Preclinical trials in Rheumatoid arthritis in Japan (PO)
- 05 Nov 2017 Pharmacodynamics and adverse event data from a preclinical study in Rheumatoid arthritis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)